RxDoctor Payments Data

Willow Brasher, NP

Family · Boise, IDNPI 1548913064

Payments from drug & device makers

$966in general payments, 2019–2025

Across 20 payments — averaging $48.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$377
  • Boston Scientific$136
  • Alnylam Pharmaceuticals Inc.$112
  • E.r. Squibb & Sons, L.L.C.$111
  • Irhythm Technologies, Inc.$91
  • Pfizer$90
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$966100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$966 in reported general payments places this provider in the 70th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$46,447
Medicare patients
289
Services billed
923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban253$297,994
JardianceEmpagliflozin206$173,793
EntrestoSacubitril/Valsartan102$88,844
Repatha SureclickEvolocumab78$76,988
XareltoRivaroxaban63$62,557
FarxigaDapagliflozin Propanediol48$54,585
Praluent PenAlirocumab13$12,229
Metoprolol Succinate550$6,982
Ranolazine ErRanolazine13$5,244
Potassium Chloride220$4,713
Rosuvastatin Calcium342$4,032
Atorvastatin Calcium423$3,837
Torsemide236$3,773
Ezetimibe141$3,233
Diltiazem 24hr Er (Cd)Diltiazem Hcl42$1,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$90$297,994253 claims
Boehringer IngelheimJardiance$16$173,793206 claims
Johnson & JohnsonXarelto$15$62,55763 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 809 family providers in Idaho.

Other family in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →